Status:
RECRUITING
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Lead Sponsor:
Miltenyi Biomedicine GmbH
Conditions:
Non Hodgkin Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
Detailed Description
This is a non-therapeutic study design. After successful screening, subjects will be monitored for potential gene therapy-related adverse events for up to 15 years post MB-CART2019.1 infusion. Subject...
Eligibility Criteria
Inclusion
- Received zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study and have either completed the study or have discontinued early from the study.
- Provided written informed consent to participate in this study.
Exclusion
- None
Key Trial Info
Start Date :
May 15 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2039
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06116110
Start Date
May 15 2024
End Date
December 1 2039
Last Update
November 20 2024
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University
Stanford, California, United States, 94305
2
Yale University
New Haven, Connecticut, United States, 06520
3
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, United States, 21201
4
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215